Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(0)
•••
Comment by princeofcuton Jul 22, 2015 4:25pm
131 Views
Post# 23950311

RE:RE:News: Bioasis, Harvard teaching hospital to work with Transc

RE:RE:News: Bioasis, Harvard teaching hospital to work with Transcmoney, don't let pikupstix rube you out and make a bagholder of you...the NR was worth about the reaction it got...so you should ask why did pikupstix pump it like it was the 2nd coming of the miracle... in a nut shell he is paid by BTI and you should never forget that..it will take years for anything to come to fruitition and i guess pikupstix don't know that... but it is pre-clinical work then PI, then PII and then PIII, 10 years i guess...and the brain cancer field is very crowded, BTI will not be the focal point as pikupstix (exposing his incompetence i guess) spews...as i posted earlier i know of a least 1 babybiotech who has an ODD for malignant glioma (a very broad license) but they like BTI and anyone else still has to conduct successful trial...ps who all on this MB are part of the pikupstix cabal???ps Harvard is on par with a number of other good centres in the US...seems pikupstix don't know that either or maybe he does and just pumps WABS to you all
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities